Nasim Tabrizi

Dermaliq Therapeutics is a clinical-stage pharmaceutical company focused on developing next-generation topical dermatological therapies. Spun out from Novaliq, the company utilizes a proprietary Semi-Fluorinated Alkanes (SFA) technology platform to enhance the bioavailability and stability of active ingredients without the need for surfactants or preservatives. Its lead programs include DLQ01 for androgenetic alopecia and DLQ02 for psoriasis, both of which have demonstrated promising results in clinical trials. Dermaliq aims to transform the treatment landscape for skin diseases by providing more effective, stable, and patient-friendly topical solutions.